If you are interested in participating in the EJS ACT-PD trial, you will need to first complete the Registration of Interest.
Visit our Registration of Interest Page for more information and to find the link to the Registration Form.
We are pleased to share that the EJS ACT-PD trial team will now investigate Ursodeoxycholic acid (UDCA) as a potential disease-modifying treatment for Parkinson’s disease (PD)! UDCA will be added as a new active drug treatment in the trial. The UDCA treatment has a different dosing regimen to the two treatments already being tested (telmisartan and terazosin). This means another control (placebo) group will also be added to the trial, to match the UDCA
tablets. Neither you nor the study team will know whether you have been assigned one of the treatments or a placebo whilst the trial is taking place.
Participants who join the trial from now on will be randomly assigned to one of the five treatment groups depending on which they are eligible for. Eligibility is determined by the initial screening tests you take before starting the trial. Participants will only be assigned to a treatment group that the tests show it is safe for them to take.
Three of these groups are active drug treatments and two are the control (placebo) groups:
Group A: a once-a-day placebo capsule (or dummy drug) plus your usual care for PD
Group B: Telmisartan (40mg per day taken once-a-day) plus your usual care for PD
Group C: Terazosin (5mg per day taken once-a-day) plus your usual care for PD
Group D: UDCA (1,500mg to 2500mg per day) split between 3, 4 or 5 tablets taken at three separate times during the day plus your usual care for PD
Group E: 3, 4 or 5 placebo tablets (or dummy drug) taken at three separate times during the day plus your usual care for PD
A PDF version of the questions can also be downloaded - UDCA Q&A Sheet
What is UDCA?
UDCA is a treatment currently used to treat certain liver conditions. This means that we already understand its safety and possible side effects.
Why was UDCA chosen for testing in the trial?
Research suggests that UDCA may help protect brain cells by improving the function of mitochondria, the structures which are responsible for producing energy within cells, and are believed to play an important role in PD. Previous clinical studies of UDCA in people with PD have also shown promising improvements in walking and mobility.
How is UDCA taken?
Participants randomised to the three times a day regimen (UDCA or matching placebo) will take either 3, 4 or 5 tablets each day, depending on their body weight. The site trial teams will check participants weight at their first in-person appointment. These tablets are taken at three separate times during the day. UDCA should also be taken with food or immediately after food.
What are the side effects of UDCA?
The most common, important side effects of UDCA are:
Participants may experience none, some, or all the side effects.
Does this mean UDCA is better than the other treatments?
The addition of UDCA as a third treatment arm does not mean it is expected to be more or less effective than the other treatments being studied. All three treatments have been selected following a careful review of all the evidence which includes previous research studies which show their potential as disease-modifying treatments for Parkinson’s. The EJS ACT-PD trial aims to find out whether any of these treatments are effective at slowing or stopping the progression of PD.
Why was UDCA selected to start later than the other treatments?
UDCA was selected as a trial treatment at the same time as the first two trial arms (telmisartan and terazosin). However, it was decided that UDCA would start around 12 months after the trial opened for two reasons:
Who can be randomised to the UDCA arm?
Only new participants who have their screening visit after the UDCA arm has opened may be randomised to receive UDCA. As with all treatments in the trial, participants will complete safety checks to make sure they are able to take part in the trial and to check if it is safe for them to take UDCA.
If you have already had your screening visit, or are already taking medication assigned to you as part of the trial, please continue following the instructions provided to you by your site trial team.
Can I choose which treatment group I am assigned to?
No one who takes part in the trial can choose their treatment group. This includes not being able to choose whether they are assigned to the once-a-day or three-times-a-day dosing schedule. Participants will be randomly assigned to a group by a computer. This means that participants will have an equal chance of being allocated to any of the groups that the tests show they can take part in.
If I withdraw from the trial, can I be re-randomised to UDCA?
If you are already taking part in the EJS ACT-PD trial, please do not withdraw from the study in the hope of being re-randomised to receive UDCA. Participants who withdraw from the trial cannot re-enter or be randomised again.
What should I do now?
If you have already completed the online registration of interest form but have not yet had a telephone call or screening visit with your site, then you do not need to do anything. When you are contacted by your selected site, they will be able to discuss all treatment arms with you and answer any questions you may have. More information about the recruitment journey can be found here.
If you have not completed the registration of interest form but are thinking about joining the EJS ACT-PD trial, you should first read all 3 parts of the Participant Information Sheet. This will include information on UDCA which may not have been there when you first registered your interest. The Participant Information Sheet can be found here. The registration of interest form can be found here.
The trial team is extremely grateful for your continued participation in the trial. All of the data from every treatment arm is needed so that we can test which treatments may be effective.
Join the EJS ACT-PD Trial
If you are interested in participating in the EJS ACT-PD trial, you will need to first complete the Registration of Interest.
Visit our Registration of Interest Page for more information and to find the link to the Registration Form.